TREM2 and thymoma: Next, we examined the differential expression of TREM2 according to age for patients with each tumor type and found that those aged ≥ 65 years with LUAD (Figure 6B; p = 0.036), BRCA (Figure 6C; p = 0.0036), PRAD (Figure 6D; p = 0.0006), SARC (Figure 6E; p = 0.015), and thymoma (THYM) (Figure 6F; p = 0.035) had higher expression levels, while patients with CHOL < 65 years had higher TREM2 expression levels (Figure 6A; p = 0.0032).